Advances in Insulin and GLP-1 Therapies

Advances in insulin therapies and glucagon-like peptide-1 (GLP-1) agonists have revolutionized the treatment of diabetes. This session will focus on the latest innovations in insulin formulations, including ultra-rapid insulins and long-acting insulins that offer improved glucose control with fewer injections. Experts will also discuss the role of GLP-1 agonists in managing type 2 diabetes and obesity, highlighting their mechanisms of action and clinical benefits.

The track will examine the current clinical guidelines for insulin and GLP-1 therapy use, as well as emerging treatments and combination therapies that offer enhanced efficacy and safety profiles. Attendees will learn about ongoing clinical trials and the potential for these therapies to further improve the management of diabetes and related comorbidities.

    Related Conference of Advances in Insulin and GLP-1 Therapies

    September 29-30, 2026

    22nd World Congress on Endocrinology & Diabetes

    Paris, France
    October 20-21, 2026

    32nd World Diabetes & Heart Congress

    Amsterdam, Netherlands
    October 22-23, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada
    February 25-26, 2027

    20th International Summit on Diabetes

    London, UK
    March 23-24, 2027

    7th Annual Summit on Diabetes and Endocrinology

    Paris, France
    March 29-30, 2027

    8th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands

    Advances in Insulin and GLP-1 Therapies Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in